Increased bone marrow toxicity of doxorubicin bound to nanoparticles

The in vivo myelosuppressive effects of free and polyalkylcyanoacrylate-bound doxorubicin were compared in a mouse model. After intravenous administration of 11 mg/kg body weight of doxorubicin either free or bound to polyisobutyl (doxo-PIBCA) or polyisohexylcyanoacrylate (doxo-PIHCA) nanoparticles,...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 30A; no. 6; pp. 820 - 826
Main Authors Gibaud, Stéphane, Jean-Paul, Andreux, Weingarten, Colette, Renard, Michèle, Couvreur, Patrick
Format Journal Article
LanguageEnglish
Published Elsevier 1994
Subjects
Cancer
Galenic pharmacology
Life Sciences
Medication
Pharmaceutical sciences
drug carriers
stem cells
cyanoacrylates
doxorubicin
bone marrow
Online AccessGet full text

Cover

More Information
Summary:The in vivo myelosuppressive effects of free and polyalkylcyanoacrylate-bound doxorubicin were compared in a mouse model. After intravenous administration of 11 mg/kg body weight of doxorubicin either free or bound to polyisobutyl (doxo-PIBCA) or polyisohexylcyanoacrylate (doxo-PIHCA) nanoparticles, we studied the total and differential counts of blood, bone marrow and spleen cells; the number of granulocyte progenitors (CFU-GM) was determined by culture. Doxorubicin concentrations were measured with an HPLC method in the bone marrow and the spleen. Doxo-PIHCA nanoparticles showed the highest and longest myelosuppressive effects which correlated well with a high concentration of the drug in the bone marrow and the spleen. Moreover, it was found that PIHCA nanoparticles induced the release of colony stimulating factors, which might account for the observed increase of toxic effects of doxorubicin on bone marrow progenitors. These data also indicate that a more precise evaluation of the myelosuppressive effects of targeted formulations of anticancer drugs is needed, which may be attained by studies on bone marrow progenitors.
ISSN:0959-8049
DOI:10.1016/0959-8049(94)90299-2